Drug Discovery Services Market

Drug Discovery Services Market Analysis by Process (Target Selection, Target Validation, Hit-To-Lead Identification), by Type (Medicinal Chemistry, Biology Services, Pharmacokinetics), by Drug Type (Small Molecules and Biologics) by Therapeutic Area, by Region - Global Market Insights 2022 to 2032

Analysis of Drug Discovery Services market covering 30 + countries including analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more

Drug Discovery Services Market Outlook (2022 to 2032)

The drug discovery services market is forecasted to reach US$ 50 Billion by 2032, up from US$ 19 Billion in 2022, at a CAGR of 10.1%.

A Y-o-Y growth rate of nearly 12% is expected for the market in 2022. As of 2021, the market was valued at US$ 17 Billion.

Report Attributes Details
Anticipated Base Year Value (2021) US$ 17 Billion
Expected Market Value (2022) US$ 19 Billion
Projected Forecast Value (2032) US$ 50 Billion
Global Growth Rate (2022 to 2032) 10.1% CAGR
Growth Rate of the U.S (2022 to 2032) 9.8% CAGR
Expected Market Value of China (2032) US$ 15 Billion
Key Drug Discovery Services Service Providers Syngene; Wuxi Apptec; Urigene Discovery Technologies; Genscript Biotech Corporation; Covance; Jubilant Biosys; Pharmaceutical Product Development, LLC. (PPD); Evotec; Charles River Laboratories International; Albany Molecular Research Inc. (AMRI); GE Healthcare; Merck Millipore; Thermo Fisher Scientific Inc.

Growing R&D expenditure in the pharmaceutical and biopharmaceutical industries, rising demand for outsourcing analytical testing services, initiatives for research on rare diseases and orphan drugs, and the high cost of in-house drug development are all creating new revenue pockets in the drug discovery services market.

Furthermore, factors such as rising R&D expenditure in the pharmaceutical and biopharmaceutical industries, rising initiatives for research on rare diseases and orphan drugs, a rapidly growing focus on drug discovery and a proliferating pharmaceutical industry are all expected to influence market growth in the future.

Don't Need a Global Report?

save 40%! on Country & Region specific reports

Drug Discovery Services Market Revenue Analysis 2015 to 2021 vs. Future Outlook 2022 to 2032

According to Fact.MR, the global market for drug discovery services is expected to increase rapidly. The global market for drug discovery services is expected to generate US$ 50 Billion in sales by the end of 2032. Advances in drug discovery technology are resulting in improved drug discovery services.

Some of the market's forthcoming trends in drug discovery technology include regulatory initiatives toward Pharmacogenomic technology, combinatorial chemistry technology, and so on. There has also been a rise in the use of label-free methods. Increased R&D efforts and spending, as well as pharmaceutical businesses shifting to outsourcing, are some of the causes driving the expansion of drug discovery services.

The use of improved technologies in the drug development process is also a key driver of market expansion. However, severe rules in certain jurisdictions on drug discovery services, high costs associated with drug research and development, and the use of animals in testing are stifling industry growth.

Prominent Drug Discovery Services Industry Growth Drivers

Increasing R&D Spending in Pharmaceutical and Biopharma Businesses

Most pharmaceutical, biopharmaceutical, and medical device businesses make significant investments in the development of new medications and technologies. The pharmaceutical sector is heavily invested in R&D. Pharmaceutical firms spend in R&D in order to bring high-quality, innovative medicines to market.

According to trends, the leading pharma firms are enhancing their R&D efficiency through large R&D investments to realize long-term benefits and joint R&D efforts. According to the EvaluatePharma analysis, global pharmaceutical R&D investment was valued at US$ 137 billion in 2012, and is expected to climb to US$ 198 billion by 2020. As a result of the COVID-19 pandemic, the worldwide pharmaceutical R&D growth rate is expected to fall to 0.1% in 2020. According to the analysis, R&D spending is predicted to expand gradually at a CAGR of 4.2% between 2020 and 2026 to reach USD 254.0 billion, slower than the historical CAGR of 4.7% between 2012 and 2020.

Pharmaceutical and biopharmaceutical businesses' increasing R&D expenditures are leading them to seek fully integrated or functional outsourcing services for drug research and development, from the early development stage through the late-stage development phase. Outsourcing has grown as a strategic solution to offset the shortage of in-house resources necessary for new product development as pharma businesses face great pressure to limit fixed costs. Large pharmaceutical corporations are shifting to a leaner business strategy that mainly depends on outsourcing.

Most pharmaceutical and biopharmaceutical businesses outsource their testing services throughout R&D to increase profitability, meet drug development timeframes, and save money. This is evidenced by recent collaborations between large pharmaceutical corporations and contract research organizations (CROs) that provide drug discovery and development services.

As a result, rising pharmaceutical R&D spending fuels the development of the drug discovery services industry.

Constant Research to find a Cure for COVID-19 widened Expansion Prospects

The COVID-19 pandemic provided a massive boost to the pharmaceutical industry, in terms of the number of medications authorized by the US FDA. This year saw the approval of 53 medications, which was only topped in 2018 with 59 pharmaceutical agents.

In 2020, there were 53 approvals totaling 40 novel chemical entities and 13 biologics (of which ten were monoclonal antibodies, two were antibody-drug conjugates, and three were peptides, and two, oligonucleotides). In the previous three years (2018 to 2020), the FDA approved 160 medications, compared to only 21 in 2010.

This increase in the number of authorized drugs globally can be linked to increased biopharmaceutical company spending in the development of biologics and biosimilars. Biologics, such as proteins, peptides, and monoclonal antibodies, account for more than half of the therapeutic candidates in the discovery stage. In 2022, biologics are predicted to account for about half of the revenue earned by the top 100 pharmaceutical product sales.

Despite the fact that small-molecule pharmaceuticals dominate the global pharmaceutical industry, the share of biologics, biosimilars, and large-molecule medications is increasing, owing to the introduction of new biologic-based treatments and rising earnings from current biologics.

At each level, biologics and biosimilars need more specialized testing services than small molecules. The growing demand for these services to be outsourced to CROs is likely to boost the demand of the drug discovery services market in the coming years.

More Insights, Lesser Cost (-50% off)

Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR

Key Challenges Prevalent in the Global Drug Discovery Services Market

Strict Guidelines Control Drug Development and Animal Testing

Regulatory agencies' primary priority during medication approval is ensuring safety and efficacy. Although these procedures serve to assure the quality of medicines that are released to the market, they significantly raise the cost of medication research and the final product. This aspect can have a major influence on medicine adoption in price-sensitive emerging economies. Aside from that, different legislations that protect product quality (such as GMP) sometimes raise production prices.

Animals are used in drug development under strict limits. Mice, rats, fish, amphibians, and reptiles are the most common animals utilized in research. Concerns over the ethical use of animals in research have prompted countries to enact animal safety and usage regulations, which pose a number of hurdles to the smooth operation of drug discovery research.

Companies have been obliged to find other methods to reduce animal use as a result of this. Novo Nordisk, for example, employs biosimulation, which entails employing computer models to imitate human biology. However, this has not been fully implemented throughout the sector.

Country-wise Analysis

What is the Growth Outlook for Drug Discovery Services in the U.S?

United States to lead the Drug Discovery Services Market

In terms of pharmaceutical R&D investment, United States leads the globe. It is also the most important market for both bulk pharmaceuticals and final dosage formulations. The market works as a free economy, with the goal of implementing transparent trading processes and restricting anti-competitive behavior.

Over the projection period, a significant push for generic pharmaceuticals and biosimilars is likely to enhance demand for specialty and complex ingredients. For example, Bayer entered into a partnership arrangement with the artificial intelligence drug discovery services business Exscientia in January 2020 to develop and optimize innovative lead structures for prospective therapeutic candidates in the treatment of cardiovascular and Oncological disorders. Because biologics are more expensive, the country has a lot of prospects for biosimilars.

The COVID-19 pandemic underlined the importance of North American corporations and research groups collaborating with the government to create new medications to address future health catastrophes. Several universities and significant businesses are engaged on creating corona virus vaccines. For example, Eli Lilly collaborated with AbCellera to create vaccinations.

How do Growth Prospects appear in the Chinese Market?

Rising Demand for Drug Discovery Informatics is Attributable to the Expanding Population Base and Growth in the Prevalence of Infectious Illnesses. Because of the vast number of skilled researchers and low-cost operations in rising nation such as China, Asia-Pacific is predicted to increase at a high rate from 2022 to 2032. Emerging as the pinnacle of the global telecommunications and digital China is a valuable market.

During the forecast period, the drug discovery services market in the area is expected to increase at a quick pace. An increase in government efforts is expected to strengthen China’s market share. Increased need for drug discovery informatics in China is ascribed to a huge population base and an increase in the prevalence of infectious illnesses. In the next years, China is expected to provide considerable prospects to the drug discovery services industry.

Country-wise Forecast CAGRs in the Drug Discovery Services Market

Country wise Analysis Growth Rate
U.S 9.8%
U.K 9%
China 9.7%
Japan 8.5%
South Korea 7.6%

Know thy Competitors

Competitive landscape highlights only certain players
Complete list available upon request

Category-wise Insights

Why Medicinal Chemistry is the Most Preferred Type?

Medicinal Chemistry will be the Most Common Type of Drug Discovery Service

Medicinal chemistry is expected to be the most popular service type in the drug discovery services industry. Medicinal chemistry is expected to generate about US$ 6 Billion in revenue.

Outsourcing by pharmaceutical companies has increased, and this is emerging as a driving element. Many Asian drug discovery service companies are expanding their presence in North America and Europe.

Why is Demand for Small Molecules Rising Rapidly?

Small Molecules to Experience the Most Revenue Growth

Small molecules are expected to account for the greatest share of revenue when compared to biologics. Small molecules are expected to generate more than US$ 10.8 Billion in revenue by the end of 2032.

Small molecules are gaining popularity because they are simple, easy to describe, and well defined. Small chemicals can also readily infiltrate cells and kill cancer cells.

Which Therapeutic Area will Leverage Drug Discovery Services the Most?

Oncology will have the Highest Revenue Share in the Therapeutic Area

Oncology is expected to be the greatest therapeutic area during the projection period. Oncology is expected to generate more than US$ 6.9 Billion in revenue by the end of 2032.

The growing number of cancer patients has resulted in a strong need for cancer medicines. As a result, oncology is expected to develop significantly in the next years.

Competitive Landscape

The global market for Drug Discovery Services is extremely fragmented, with several large firms.

  • Eurofins Discovery and PharmaResouces announced cooperation in February 2020 to construct a combined drug discovery platform to accelerate the development of small-molecule pharmaceuticals.

Key Segments Covered in the Drug Discovery Services Industry Report

  • By Process :

    • Target Selection
    • Target Validation
    • Hit-To-Lead Identification
    • Lead Optimization
    • Candidate Validation

  • By Type :

    • Medicinal Chemistry
    • Biology Services
    • Drug Metabolism and Pharmacokinetics

  • By Drug Type :

    • Small Molecules
    • Biologics

  • By Therapeutic Area :

    • Oncology
    • Neurology
    • Cardiovascular Diseases
    • Respiratory Diseases
    • Diabetes and Other Therapeutic Areas

  • By Region :

    • North America
    • Latin America
    • Europe
    • Asia Pacific
    • Middle East & Africa

Table of Content

  • 1. Global Economic Outlook
  • 2. Global Market - Executive Summary
  • 3. Global Market Overview
  • 4. Global Market Analysis and Forecast 2015 to 2032
    • 4.1. Global Market Size and Forecast by Process, 2015 to 2032
      • 4.1.1. Target Selection
      • 4.1.2. Target Validation
      • 4.1.3. Hit-To-Lead Identification
      • 4.1.4. Lead Optimization
      • 4.1.5. Candidate Validation
    • 4.2. Global Market Size and Forecast By Type, 2015 to 2032
      • 4.2.1. Medicinal Chemistry
      • 4.2.2. Biology Services
      • 4.2.3. Drug Metabolism and Pharmacokinetics
    • 4.3. Global Market Size and Forecast By Drug Type, 2015 to 2032
      • 4.3.1. Small Molecules
      • 4.3.2. Biologics
    • 4.4. Global Market Size and Forecast By Therapeutic Area, 2015 to 2032
      • 4.4.1. Oncology
      • 4.4.2. Neurology
      • 4.4.3. Respiratory Diseases
      • 4.4.4. Cardiovascular Diseases
      • 4.4.5. Diabetes
      • 4.4.6. Other Therapeutic Areas
  • 5. North America Market Size and Forecast, 2015 to 2032
  • 6. Latin America Market Size and Forecast, 2015 to 2032
  • 7. Europe Market Size and Forecast, 2015 to 2032
  • 8. Japan Market Size and Forecast, 2015 to 2032
  • 9. APEJ Market Size and Forecast, 2015 to 2032
  • 10. MEA Market Size and Forecast, 2015 to 2032
  • 11. Global Market Company Share, Competition Landscape and Company Profiles
    • 11.1. Thermo Fisher Scientific, Inc.
    • 11.2. GE Healthcare
    • 11.3. Charles River Laboratories International
    • 11.4. Agilent Technologies, Inc.
    • 11.5. Eli Lilly and Company
    • 11.6. Lonza Group Ltd
    • 11.7. WuXi AppTec Co. Ltd.
    • 11.8. Evotec AG
    • 11.9. Pharmaceutical Product Development LLC
    • 11.10. Merck Millipore
    • 11.11. Albany Molecular Research, Inc.
    • 11.12. Covance Inc.
    • 11.13. Genscript Biotech Corporation
    • 11.14. Aurigene Discovery Technologies Limited
    • 11.15. Syngene International Limited
    • 11.16. Promega Corporation
    • 11.17. SRI International, Inc.
    • 11.18. Chembridge Corporation
    • 11.19. GVK Biosciences Private Limited
    • 11.20. Domainex Ltd.
    • 11.21. Selcia Limited
    • 11.22. Viva Biotech Ltd.
    • 11.23. Jubilant Biosys Limited
    • 11.24. Ubiquigent Limited
    • 11.25. ReproCELL, Inc.
    • 11.26. DiscoverX Corporation
    • 11.27. Creative Bioarray
  • 12. Research Methodology
  • 13. Secondary and Primary Sources
  • 14. Assumptions and Acronyms
  • 15. Disclaimer

Don't Need a Global Report?

save 40%! on Country & Region specific reports

List Of Table

TABLE 1 Global Market Value (US$ Mn), 2015 to 2021

TABLE 2 Global Market Value (US$ Mn), 2022 to 2032

TABLE 3 Global Market Value (US$ Mn) and Y-o-Y, 2022 to 2032

TABLE 4 Global Target Selection Segment Value (US$ Mn), By Region 2015 to 2021

TABLE 5 Global Target Selection Segment Value (US$ Mn), By Region 2022 to 2032

TABLE 6 Global Target Selection Segment Market Share, By Region 2015 to 2021

TABLE 7 Global Target Selection Segment Market Share, By Region 2022 to 2032

TABLE 8 Global Target Selection Segment Y-o-Y, By Region 2022 to 2032

TABLE 9 Global Target Validation Segment Value (US$ Mn), By Region 2015 to 2021

TABLE 10 Global Target Validation Segment Value (US$ Mn), By Region 2022 to 2032

TABLE 11 Global Target Validation Segment Market Share, By Region 2015 to 2021

TABLE 12 Global Target Validation Segment Market Share, By Region 2022 to 2032

TABLE 13 Global Target Validation Segment Y-o-Y, By Region 2022 to 2032

TABLE 14 Global Hit-To-Lead Identification Segment Value (US$ Mn), By Region 2015 to 2021

TABLE 15 Global Hit-To-Lead Identification Segment Value (US$ Mn), By Region 2022 to 2032

TABLE 16 Global Hit-To-Lead Identification Segment Market Share, By Region 2015 to 2021

TABLE 17 Global Hit-To-Lead Identification Segment Market Share, By Region 2022 to 2032

TABLE 18 Global Hit-To-Lead Identification Segment Y-o-Y, By Region 2022 to 2032

TABLE 19 Global Lead Optimization Segment Value (US$ Mn), By Region 2015 to 2021

TABLE 20 Global Lead Optimization Segment Value (US$ Mn), By Region 2022 to 2032

TABLE 21 Global Lead Optimization Segment Market Share, By Region 2015 to 2021

TABLE 22 Global Lead Optimization Segment Market Share, By Region 2022 to 2032

TABLE 23 Global Lead Optimization Segment Y-o-Y, By Region 2022 to 2032

TABLE 24 Global Candidate Validation Segment Value (US$ Mn), By Region 2015 to 2021

TABLE 25 Global Candidate Validation Segment Value (US$ Mn), By Region 2022 to 2032

TABLE 26 Global Candidate Validation Segment Market Share, By Region 2015 to 2021

TABLE 27 Global Candidate Validation Segment Market Share, By Region 2022 to 2032

TABLE 28 Global Candidate Validation Segment Y-o-Y, By Region 2022 to 2032

TABLE 29 Global Medicinal Chemistry Segment Value (US$ Mn), By Region 2015 to 2021

TABLE 30 Global Medicinal Chemistry Segment Value (US$ Mn), By Region 2022 to 2032

TABLE 31 Global Medicinal Chemistry Segment Market Share, By Region 2015 to 2021

TABLE 32 Global Medicinal Chemistry Segment Market Share, By Region 2022 to 2032

TABLE 33 Global Medicinal Chemistry Segment Y-o-Y, By Region 2022 to 2032

TABLE 34 Global Biology Services Segment Value (US$ Mn), By Region 2015 to 2021

TABLE 35 Global Biology Services Segment Value (US$ Mn), By Region 2022 to 2032

TABLE 36 Global Biology Services Segment Market Share, By Region 2015 to 2021

TABLE 37 Global Biology Services Segment Market Share, By Region 2022 to 2032

TABLE 38 Global Biology Services Segment Y-o-Y, By Region 2022 to 2032

TABLE 39 Global Drug Metabolism and Pharmacokinetics Segment Value (US$ Mn), By Region 2015 to 2021

TABLE 40 Global Drug Metabolism and Pharmacokinetics Segment Value (US$ Mn), By Region 2022 to 2032

TABLE 41 Global Drug Metabolism and Pharmacokinetics Segment Market Share, By Region 2015 to 2021

TABLE 42 Global Drug Metabolism and Pharmacokinetics Segment Market Share, By Region 2022 to 2032

TABLE 43 Global Drug Metabolism and Pharmacokinetics Segment Y-o-Y, By Region 2022 to 2032

TABLE 44 Global Small Molecules Segment Value (US$ Mn), By Region 2015 to 2021

TABLE 45 Global Small Molecules Segment Value (US$ Mn), By Region 2022 to 2032

TABLE 46 Global Small Molecules Segment Market Share, By Region 2015 to 2021

TABLE 47 Global Small Molecules Segment Market Share, By Region 2022 to 2032

TABLE 48 Global Small Molecules Segment Y-o-Y, By Region 2022 to 2032

TABLE 49 Global Biologics Segment Value (US$ Mn), By Region 2015 to 2021

TABLE 50 Global Biologics Segment Value (US$ Mn), By Region 2022 to 2032

TABLE 51 Global Biologics Segment Market Share, By Region 2015 to 2021

TABLE 52 Global Biologics Segment Market Share, By Region 2022 to 2032

TABLE 53 Global Biologics Segment Y-o-Y, By Region 2022 to 2032

TABLE 54 Global Oncology Segment Value (US$ Mn), By Region 2015 to 2021

TABLE 55 Global Oncology Segment Value (US$ Mn), By Region 2022 to 2032

TABLE 56 Global Oncology Segment Market Share, By Region 2015 to 2021

TABLE 57 Global Oncology Segment Market Share, By Region 2022 to 2032

TABLE 58 Global Oncology Segment Y-o-Y, By Region 2022 to 2032

TABLE 59 Global Neurology Segment Value (US$ Mn), By Region 2015 to 2021

TABLE 60 Global Neurology Segment Value (US$ Mn), By Region 2022 to 2032

TABLE 61 Global Neurology Segment Market Share, By Region 2015 to 2021

TABLE 62 Global Neurology Segment Market Share, By Region 2022 to 2032

TABLE 63 Global Neurology Segment Y-o-Y, By Region 2022 to 2032

TABLE 64 Global Cardiovascular Diseases Segment Value (US$ Mn), By Region 2015 to 2021

TABLE 65 Global Cardiovascular Diseases Segment Value (US$ Mn), By Region 2022 to 2032

TABLE 66 Global Cardiovascular Diseases Segment Market Share, By Region 2015 to 2021

TABLE 67 Global Cardiovascular Diseases Segment Market Share, By Region 2022 to 2032

TABLE 68 Global Cardiovascular Diseases Segment Y-o-Y, By Region 2022 to 2032

TABLE 69 Global Respiratory Diseases Segment Value (US$ Mn), By Region 2015 to 2021

TABLE 70 Global Respiratory Diseases Segment Value (US$ Mn), By Region 2022 to 2032

TABLE 71 Global Respiratory Diseases Segment Market Share, By Region 2015 to 2021

TABLE 72 Global Respiratory Diseases Segment Market Share, By Region 2022 to 2032

TABLE 73 Global Respiratory Diseases Segment Y-o-Y, By Region 2022 to 2032

TABLE 74 Global Diabetes Segment Value (US$ Mn), By Region 2015 to 2021

TABLE 75 Global Diabetes Segment Value (US$ Mn), By Region 2022 to 2032

TABLE 76 Global Diabetes Segment Market Share, By Region 2015 to 2021

TABLE 77 Global Diabetes Segment Market Share, By Region 2022 to 2032

TABLE 78 Global Diabetes Segment Y-o-Y, By Region 2022 to 2032

TABLE 79 Global Other Therapeutic Areas Segment Value (US$ Mn), By Region 2015 to 2021

TABLE 80 Global Other Therapeutic Areas Segment Value (US$ Mn), By Region 2022 to 2032

TABLE 81 Global Other Therapeutic Areas Segment Market Share, By Region 2015 to 2021

TABLE 82 Global Other Therapeutic Areas Segment Market Share, By Region 2022 to 2032

TABLE 83 Global Other Therapeutic Areas Segment Y-o-Y, By Region 2022 to 2032

TABLE 84 North America Current Expenditure on Health, (% of GDP), by Country, 2022 to 2032

TABLE 85 North America Per Capita Health Expenditure (US$ PPP), by Country, 2022 to 2032

TABLE 86 North America Per Capita Healthcare Expenditure Y-o-Y Growth (in Real terms %), by Country, 2022 to 2032

TABLE 87 North America Out-of-Pocket Healthcare Expenditure, % of Healthcare Expenditure, by Country, 2022 to 2032

TABLE 88 North America Per Capita Healthcare Expenditure (at Current Price, in US$), by Country, 2022 to 2032

TABLE 89 North America Market Value (US$ Mn), By Country 2015 to 2021

TABLE 90 North America Market Value (US$ Mn), By Country 2022 to 2032

TABLE 91 North America Market Value (US$ Mn), By Process 2015 to 2021

TABLE 92 North America Market Value (US$ Mn), By Process 2022 to 2032

TABLE 93 North America Market Value (US$ Mn), By Type 2015 to 2021

TABLE 94 North America Market Value (US$ Mn), By Type 2022 to 2032

TABLE 95 North America Market Value (US$ Mn), By Drug Type 2015 to 2021

TABLE 96 North America Market Value (US$ Mn), By Drug Type 2022 to 2032

TABLE 97 North America Market Value (US$ Mn), By Therapeutic Area 2015 to 2021

TABLE 98 North America Market Value (US$ Mn), By Therapeutic Area 2022 to 2032

TABLE 99 Latin America Current Expenditure on Health, (% of GDP), by Country, 2022 to 2032

TABLE 100 Latin America Per Capita Health Expenditure (US$ PPP), by Country, 2022 to 2032

TABLE 101 Latin America Per Capita Healthcare Expenditure Y-o-Y Growth (in Real terms %), by Country, 2022 to 2032

TABLE 102 Latin America Out-of-Pocket Healthcare Expenditure, % of Healthcare Expenditure, by Country, 2022 to 2032

TABLE 103 Latin America Per Capita Healthcare Expenditure (at Current Price, in US$), by Country, 2022 to 2032

TABLE 104 Latin America Market Value (US$ Mn), By Country 2015 to 2021

TABLE 105 Latin America Market Value (US$ Mn), By Country 2022 to 2032

TABLE 106 Latin America Market Value (US$ Mn), By Process 2015 to 2021

TABLE 107 Latin America Market Value (US$ Mn), By Process 2022 to 2032

TABLE 108 Latin America Market Value (US$ Mn), By Type 2015 to 2021

TABLE 109 Latin America Market Value (US$ Mn), By Type 2022 to 2032

TABLE 110 Latin America Market Value (US$ Mn), By Drug Type 2015 to 2021

TABLE 111 Latin America Market Value (US$ Mn), By Drug Type 2022 to 2032

TABLE 112 Latin America Market Value (US$ Mn), By Therapeutic Area 2015 to 2021

TABLE 113 Latin America Market Value (US$ Mn), By Therapeutic Area 2022 to 2032

TABLE 114 Europe Current Expenditure on Health, (% of GDP), by Country, 2022 to 2032

TABLE 115 Europe Per Capita Health Expenditure (US$ PPP), by Country, 2022 to 2032

TABLE 116 Europe Per Capita Healthcare Expenditure Y-o-Y Growth (in Real terms %), by Country, 2022 to 2032

TABLE 117 Europe Out-of-Pocket Healthcare Expenditure, % of Healthcare Expenditure, by Country, 2022 to 2032

TABLE 118 Europe Per Capita Healthcare Expenditure (at Current Price, in US$), by Country, 2022 to 2032

TABLE 119 Europe Market Value (US$ Mn), By Country 2015 to 2021

TABLE 120 Europe Market Value (US$ Mn), By Country 2022 to 2032

TABLE 121 Europe Market Value (US$ Mn), By Process 2015 to 2021

TABLE 122 Europe Market Value (US$ Mn), By Process 2022 to 2032

TABLE 123 Europe Market Value (US$ Mn), By Type 2015 to 2021

TABLE 124 Europe Market Value (US$ Mn), By Type 2022 to 2032

TABLE 125 Europe Market Value (US$ Mn), By Drug Type 2015 to 2021

TABLE 126 Europe Market Value (US$ Mn), By Drug Type 2022 to 2032

TABLE 127 Europe Market Value (US$ Mn), By Therapeutic Area 2015 to 2021

TABLE 128 Europe Market Value (US$ Mn), By Therapeutic Area 2022 to 2032

TABLE 129 Japan Current Expenditure on Health, (% of GDP), by Country, 2022 to 2032

TABLE 130 Japan Per Capita Health Expenditure (US$ PPP), by Country, 2022 to 2032

TABLE 131 Japan Per Capita Healthcare Expenditure Y-o-Y Growth (in Real terms %), by Country, 2022 to 2032

TABLE 132 Japan Out-of-Pocket Healthcare Expenditure, % of Healthcare Expenditure, by Country, 2022 to 2032

TABLE 133 Japan Per Capita Healthcare Expenditure (at Current Price, in US$), by Country, 2022 to 2032

TABLE 134 Japan Market Value (US$ Mn), By Country 2015 to 2021

TABLE 135 Japan Market Value (US$ Mn), By Country 2022 to 2032

TABLE 136 Japan Market Value (US$ Mn), By Process 2015 to 2021

TABLE 137 Japan Market Value (US$ Mn), By Process 2022 to 2032

TABLE 138 Japan Market Value (US$ Mn), By Type 2015 to 2021

TABLE 139 Japan Market Value (US$ Mn), By Type 2022 to 2032

TABLE 140 Japan Market Value (US$ Mn), By Drug Type 2015 to 2021

TABLE 141 Japan Market Value (US$ Mn), By Drug Type 2022 to 2032

TABLE 142 Japan Market Value (US$ Mn), By Therapeutic Area 2015 to 2021

TABLE 143 Japan Market Value (US$ Mn), By Therapeutic Area 2022 to 2032

TABLE 144 APEJ Current Expenditure on Health, (% of GDP), by Country, 2022 to 2032

TABLE 145 APEJ Per Capita Health Expenditure (US$ PPP), by Country, 2022 to 2032

TABLE 146 APEJ Per Capita Healthcare Expenditure Y-o-Y Growth (in Real terms %), by Country, 2022 to 2032

TABLE 147 APEJ Out-of-Pocket Healthcare Expenditure, % of Healthcare Expenditure, by Country, 2022 to 2032

TABLE 148 APEJ Per Capita Healthcare Expenditure (at Current Price, in US$), by Country, 2022 to 2032

TABLE 149 APEJ Market Value (US$ Mn), By Country 2015 to 2021

TABLE 150 APEJ Market Value (US$ Mn), By Country 2022 to 2032

TABLE 151 APEJ Market Value (US$ Mn), By Process 2015 to 2021

TABLE 152 APEJ Market Value (US$ Mn), By Process 2022 to 2032

TABLE 153 APEJ Market Value (US$ Mn), By Type 2015 to 2021

TABLE 154 APEJ Market Value (US$ Mn), By Type 2022 to 2032

TABLE 155 APEJ Market Value (US$ Mn), By Drug Type 2015 to 2021

TABLE 156 APEJ Market Value (US$ Mn), By Drug Type 2022 to 2032

TABLE 157 APEJ Market Value (US$ Mn), By Therapeutic Area 2015 to 2021

TABLE 158 APEJ Market Value (US$ Mn), By Therapeutic Area 2022 to 2032

TABLE 159 MEA Current Expenditure on Health, (% of GDP), by Country, 2022 to 2032

TABLE 160 MEA Per Capita Health Expenditure (US$ PPP), by Country, 2022 to 2032

TABLE 161 MEA Per Capita Healthcare Expenditure Y-o-Y Growth (in Real terms %), by Country, 2022 to 2032

TABLE 162 MEA Out-of-Pocket Healthcare Expenditure, % of Healthcare Expenditure, by Country, 2022 to 2032

TABLE 163 MEA Per Capita Healthcare Expenditure (at Current Price, in US$), by Country, 2022 to 2032

TABLE 164 MEA Market Value (US$ Mn), By Country 2015 to 2021

TABLE 165 MEA Market Value (US$ Mn), By Country 2022 to 2032

TABLE 166 MEA Market Value (US$ Mn), By Process 2015 to 2021

TABLE 167 MEA Market Value (US$ Mn), By Process 2022 to 2032

TABLE 168 MEA Market Value (US$ Mn), By Type 2015 to 2021

TABLE 169 MEA Market Value (US$ Mn), By Type 2022 to 2032

TABLE 170 MEA Market Value (US$ Mn), By Drug Type 2015 to 2021

TABLE 171 MEA Market Value (US$ Mn), By Drug Type 2022 to 2032

TABLE 172 MEA Market Value (US$ Mn), By Therapeutic Area 2015 to 2021

TABLE 173 MEA Market Value (US$ Mn), By Therapeutic Area 2022 to 2032

More Insights, Lesser Cost (-50% off)

Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR

List Of Figures

FIG. 1 Global Market Value (US$ Mn), 2015 to 2021

FIG. 2 Global Market Value (US$ Mn) Forecast, 2022 to 2032

FIG. 3 Global Market Value (US$ Mn) and Y-o-Y, 2022 to 2032

FIG. 4 Global Target Selection Segment Market Value (US$ Mn) By Region, 2015 to 2021

FIG. 5 Global Target Selection Segment Market Value (US$ Mn) By Region, 2022 to 2032

FIG. 6 Global Target Selection Segment Y-o-Y Growth Rate, By Region, 2022 to 2032

FIG. 7 Global Target Validation Segment Market Value (US$ Mn) By Region, 2015 to 2021

FIG. 8 Global Target Validation Segment Market Value (US$ Mn) By Region, 2022 to 2032

FIG. 9 Global Target Validation Segment Y-o-Y Growth Rate, By Region, 2022 to 2032

FIG. 10 Global Hit-To-Lead Identification Segment Market Value (US$ Mn) By Region, 2015 to 2021

FIG. 11 Global Hit-To-Lead Identification Segment Market Value (US$ Mn) By Region, 2022 to 2032

FIG. 12 Global Hit-To-Lead Identification Segment Y-o-Y Growth Rate, By Region, 2022 to 2032

FIG. 13 Global Lead Optimization Segment Market Value (US$ Mn) By Region, 2015 to 2021

FIG. 14 Global Lead Optimization Segment Market Value (US$ Mn) By Region, 2022 to 2032

FIG. 15 Global Lead Optimization Segment Y-o-Y Growth Rate, By Region, 2022 to 2032

FIG. 16 Global Candidate Validation Segment Market Value (US$ Mn) By Region, 2015 to 2021

FIG. 17 Global Candidate Validation Segment Market Value (US$ Mn) By Region, 2022 to 2032

FIG. 18 Global Candidate Validation Segment Y-o-Y Growth Rate, By Region, 2022 to 2032

FIG. 19 Global Medicinal Chemistry Segment Market Value (US$ Mn) By Region, 2015 to 2021

FIG. 20 Global Medicinal Chemistry Segment Market Value (US$ Mn) By Region, 2022 to 2032

FIG. 21 Global Medicinal Chemistry Segment Y-o-Y Growth Rate, By Region, 2022 to 2032

FIG. 22 Global Biology Services Segment Market Value (US$ Mn) By Region, 2015 to 2021

FIG. 23 Global Biology Services Segment Market Value (US$ Mn) By Region, 2022 to 2032

FIG. 24 Global Biology Services Segment Y-o-Y Growth Rate, By Region, 2022 to 2032

FIG. 25 Global Drug Metabolism and Pharmacokinetics Segment Market Value (US$ Mn) By Region, 2015 to 2021

FIG. 26 Global Drug Metabolism and Pharmacokinetics Segment Market Value (US$ Mn) By Region, 2022 to 2032

FIG. 27 Global Drug Metabolism and Pharmacokinetics Segment Y-o-Y Growth Rate, By Region, 2022 to 2032

FIG. 28 Global Small Molecules Segment Market Value (US$ Mn) By Region, 2015 to 2021

FIG. 29 Global Small Molecules Segment Market Value (US$ Mn) By Region, 2022 to 2032

FIG. 30 Global Small Molecules Segment Y-o-Y Growth Rate, By Region, 2022 to 2032

FIG. 31 Global Biologics Segment Market Value (US$ Mn) By Region, 2015 to 2021

FIG. 32 Global Biologics Segment Market Value (US$ Mn) By Region, 2022 to 2032

FIG. 33 Global Biologics Segment Y-o-Y Growth Rate, By Region, 2022 to 2032

FIG. 34 Global Oncology Segment Market Value (US$ Mn) By Region, 2015 to 2021

FIG. 35 Global Oncology Segment Market Value (US$ Mn) By Region, 2022 to 2032

FIG. 36 Global Oncology Segment Y-o-Y Growth Rate, By Region, 2022 to 2032

FIG. 37 Global Neurology Segment Market Value (US$ Mn) By Region, 2015 to 2021

FIG. 38 Global Neurology Segment Market Value (US$ Mn) By Region, 2022 to 2032

FIG. 39 Global Neurology Segment Y-o-Y Growth Rate, By Region, 2022 to 2032

FIG. 40 Global Cardiovascular Diseases Segment Market Value (US$ Mn) By Region, 2015 to 2021

FIG. 41 Global Cardiovascular Diseases Segment Market Value (US$ Mn) By Region, 2022 to 2032

FIG. 42 Global Cardiovascular Diseases Segment Y-o-Y Growth Rate, By Region, 2022 to 2032

FIG. 43 Global Respiratory Diseases Segment Market Value (US$ Mn) By Region, 2015 to 2021

FIG. 44 Global Respiratory Diseases Segment Market Value (US$ Mn) By Region, 2022 to 2032

FIG. 45 Global Respiratory Diseases Segment Y-o-Y Growth Rate, By Region, 2022 to 2032

FIG. 46 Global Diabetes Segment Market Value (US$ Mn) By Region, 2015 to 2021

FIG. 47 Global Diabetes Segment Market Value (US$ Mn) By Region, 2022 to 2032

FIG. 48 Global Diabetes Segment Y-o-Y Growth Rate, By Region, 2022 to 2032

FIG. 49 Global Other Therapeutic Areas Segment Market Value (US$ Mn) By Region, 2015 to 2021

FIG. 50 Global Other Therapeutic Areas Segment Market Value (US$ Mn) By Region, 2022 to 2032

FIG. 51 Global Other Therapeutic Areas Segment Y-o-Y Growth Rate, By Region, 2022 to 2032

FIG. 52 North America Market Value (US$ Mn), By Country 2015 to 2021

FIG. 53 North America Market Value (US$ Mn), By Country 2022 to 2032

FIG. 54 North America Market Value (US$ Mn), By Process 2015 to 2021

FIG. 55 North America Market Value (US$ Mn), By Process 2022 to 2032

FIG. 56 North America Market Value (US$ Mn), By Type 2015 to 2021

FIG. 57 North America Market Value (US$ Mn), By Type 2022 to 2032

FIG. 58 North America Market Value (US$ Mn), By Drug Type 2015 to 2021

FIG. 59 North America Market Value (US$ Mn), By Drug Type 2022 to 2032

FIG. 60 North America Market Value (US$ Mn), By Therapeutic Area 2015 to 2021

FIG. 61 North America Market Value (US$ Mn), By Therapeutic Area 2022 to 2032

FIG. 62 Latin America Market Value (US$ Mn), By Country 2015 to 2021

FIG. 63 Latin America Market Value (US$ Mn), By Country 2022 to 2032

FIG. 64 Latin America Market Value (US$ Mn), By Process 2015 to 2021

FIG. 65 Latin America Market Value (US$ Mn), By Process 2022 to 2032

FIG. 66 Latin America Market Value (US$ Mn), By Type 2015 to 2021

FIG. 67 Latin America Market Value (US$ Mn), By Type 2022 to 2032

FIG. 68 Latin America Market Value (US$ Mn), By Drug Type 2015 to 2021

FIG. 69 Latin America Market Value (US$ Mn), By Drug Type 2022 to 2032

FIG. 70 Latin America Market Value (US$ Mn), By Therapeutic Area 2015 to 2021

FIG. 71 Latin America Market Value (US$ Mn), By Therapeutic Area 2022 to 2032

FIG. 72 Europe Market Value (US$ Mn), By Country 2015 to 2021

FIG. 73 Europe Market Value (US$ Mn), By Country 2022 to 2032

FIG. 74 Europe Market Value (US$ Mn), By Process 2015 to 2021

FIG. 75 Europe Market Value (US$ Mn), By Process 2022 to 2032

FIG. 76 Europe Market Value (US$ Mn), By Type 2015 to 2021

FIG. 77 Europe Market Value (US$ Mn), By Type 2022 to 2032

FIG. 78 Europe Market Value (US$ Mn), By Drug Type 2015 to 2021

FIG. 79 Europe Market Value (US$ Mn), By Drug Type 2022 to 2032

FIG. 80 Europe Market Value (US$ Mn), By Therapeutic Area 2015 to 2021

FIG. 81 Europe Market Value (US$ Mn), By Therapeutic Area 2022 to 2032

FIG. 82 Japan Market Value (US$ Mn), By Country 2015 to 2021

FIG. 83 Japan Market Value (US$ Mn), By Country 2022 to 2032

FIG. 84 Japan Market Value (US$ Mn), By Process 2015 to 2021

FIG. 85 Japan Market Value (US$ Mn), By Process 2022 to 2032

FIG. 86 Japan Market Value (US$ Mn), By Type 2015 to 2021

FIG. 87 Japan Market Value (US$ Mn), By Type 2022 to 2032

FIG. 88 Japan Market Value (US$ Mn), By Drug Type 2015 to 2021

FIG. 89 Japan Market Value (US$ Mn), By Drug Type 2022 to 2032

FIG. 90 Japan Market Value (US$ Mn), By Therapeutic Area 2015 to 2021

FIG. 91 Japan Market Value (US$ Mn), By Therapeutic Area 2022 to 2032

FIG. 92 APEJ Market Value (US$ Mn), By Country 2015 to 2021

FIG. 93 APEJ Market Value (US$ Mn), By Country 2022 to 2032

FIG. 94 APEJ Market Value (US$ Mn), By Process 2015 to 2021

FIG. 95 APEJ Market Value (US$ Mn), By Process 2022 to 2032

FIG. 96 APEJ Market Value (US$ Mn), By Type 2015 to 2021

FIG. 97 APEJ Market Value (US$ Mn), By Type 2022 to 2032

FIG. 98 APEJ Market Value (US$ Mn), By Drug Type 2015 to 2021

FIG. 99 APEJ Market Value (US$ Mn), By Drug Type 2022 to 2032

FIG. 100 APEJ Market Value (US$ Mn), By Therapeutic Area 2015 to 2021

FIG. 101 APEJ Market Value (US$ Mn), By Therapeutic Area 2022 to 2032

FIG. 102 MEA Market Value (US$ Mn), By Country 2015 to 2021

FIG. 103 MEA Market Value (US$ Mn), By Country 2022 to 2032

FIG. 104 MEA Market Value (US$ Mn), By Process 2015 to 2021

FIG. 105 MEA Market Value (US$ Mn), By Process 2022 to 2032

FIG. 106 MEA Market Value (US$ Mn), By Type 2015 to 2021

FIG. 107 MEA Market Value (US$ Mn), By Type 2022 to 2032

FIG. 108 MEA Market Value (US$ Mn), By Drug Type 2015 to 2021

FIG. 109 MEA Market Value (US$ Mn), By Drug Type 2022 to 2032

FIG. 110 MEA Market Value (US$ Mn), By Therapeutic Area 2015 to 2021

FIG. 111 MEA Market Value (US$ Mn), By Therapeutic Area 2022 to 2032

Know thy Competitors

Competitive landscape highlights only certain players
Complete list available upon request

- FAQs -

What is the expected forecast CAGR for Drug Discovery Services from 2022 to 2032?

From 2022 to 2032, Drug Discovery Services demand is likely to surge at a 10.1% CAGR

At what value will the market for Drug Discovery Services close in 2032?

By 2032, the market for Drug Discovery Services is likely to be valued at US$ 50 Billion

What is the expected market value for the U.S Drug Discovery Services market?

By 2032, Fact.MR expects the U.S market for Drug Discovery Services to reach US$ 20 Billion

How opportunistic is the Chinese market for Drug Discovery Services market?

China is expected to register a 9.7% CAGR with regard to the Drug Discovery Services industry

What is the expected growth rate for the Japanese market?

Japan is expected to document a CAGR worth 8.5% in the Drug Discovery Services market

Which type will account for the maximum Drug Discovery Services revenue?

Medicinal Chemistry will expand the fastest during the forecast period.

What is the expected worth of the Drug Discovery Services industry in 2022?

By 2022, Fact.MR expected demand for Drug Discovery Services to reach US$ 19 Billion

What was the market worth for Drug Discovery Services in 2021?

As of 2021, Fact.MR estimated the Drug Discovery Services market to have reached US$ 17 Billion

At what CAGR did the Drug Discovery Services market flourish from 2015 to 2021?

From 2015 to 2021, the Drug Discovery Services market grew at an 8% value CAGR

Drug Discovery Services Market

Schedule a Call

Copyright © Fact.MR All Rights Reserved

An initiative of Eminent Research and Advisory Services